NewLink Genetics (NLNK) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of NewLink Genetics (NASDAQ:NLNK) from a buy rating to a hold rating in a research note released on Thursday.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

A number of other equities analysts have also recently issued reports on the stock. Jefferies Group reduced their price objective on shares of NewLink Genetics from $26.00 to $25.00 and set a buy rating on the stock in a research note on Friday, November 3rd. Stifel Nicolaus raised their price objective on shares of NewLink Genetics from $25.00 to $29.00 and gave the company a buy rating in a research note on Friday, November 3rd. Cantor Fitzgerald reaffirmed a buy rating and issued a $26.00 price objective on shares of NewLink Genetics in a research note on Thursday, November 2nd. Bank of America assumed coverage on shares of NewLink Genetics in a research note on Friday, October 13th. They issued a buy rating and a $22.00 price objective on the stock. Finally, ValuEngine cut shares of NewLink Genetics from a sell rating to a strong sell rating in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $23.29.

NewLink Genetics (NASDAQ NLNK) traded up $0.96 on Thursday, hitting $10.06. 2,652,600 shares of the stock traded hands, compared to its average volume of 1,470,033. NewLink Genetics has a twelve month low of $5.90 and a twelve month high of $25.17. The company has a market capitalization of $334.70, a PE ratio of -4.12 and a beta of 1.10.

A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its position in shares of NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares in the last quarter. Advisor Group Inc. boosted its position in shares of NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares in the last quarter. First Trust Advisors LP boosted its position in shares of NewLink Genetics by 11.1% during the second quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 2,859 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of NewLink Genetics by 1.8% during the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after purchasing an additional 2,865 shares in the last quarter. Finally, State Street Corp boosted its position in shares of NewLink Genetics by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 4,630 shares in the last quarter. 52.63% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “NewLink Genetics (NLNK) Lowered to “Hold” at Zacks Investment Research” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://transcriptdaily.com/2018/01/05/newlink-genetics-nlnk-lowered-to-hold-at-zacks-investment-research.html.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply